U.S., May 16 -- ClinicalTrials.gov registry received information related to the study (NCT07590310) titled 'Clinical Application of CAIX-Targeted PET Imaging in Tumors' on Dec. 11, 2025.
Brief Summary: According to the 2020 global cancer statistics, renal carcinoma ranks as the fourteenth most common malignant tumor worldwide. In 2020, there were 431,288 new cases and 179,368 deaths from renal cancer, and both the incidence and mortality rates are projected to continue rising by 2025. Early non-invasive diagnosis of clear cell renal cell carcinoma (ccRCC) is crucial for improving prognosis. Nuclear medicine molecular imaging offers the advantages of real-time, dynamic, and non-invasive detection of lesions throughout the body. However, the...